Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...

Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced ...

Monday’s edition of Forbes Daily covers simmering conflict in the Middle East, the GOP’s embrace of cannabis, Adam Neumann’s latest venture in Saudi Arabia and more.

How long will the momentum last? The post This US stock is crushing Nvidia's performance this year: Is it too late to buy?

President Joe Biden is convening the leaders of Australia, India and Japan for a Quad summit in his hometown of Wilmington, ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Frost & Sullivan grants BRAINAU the "GLOBAL COGNITIVE IMPAIMENT DIGITAL THERAPY INNOVATION AWARD " ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...